Nanjing Chuangte Pharmaceutical Technology

Nanjing Chuangte Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Nanjing, China, specializing in the discovery and development of innovative small molecule drugs. The company primarily focuses on metabolic diseases, including gout, hyperuricemia, and non-alcoholic steatohepatitis (NASH). Its lead candidate, CT-1501, is a potent and selective URAT1 inhibitor currently in clinical development for the treatment of chronic gout and hyperuricemia. Nanjing Chuangte leverages its internal research and development capabilities to advance a pipeline of candidates aimed at addressing significant unmet medical needs in the Chinese market. The company is situated in the Nanjing Jiangbei New Area, a prominent hub for biotechnology and pharmaceutical innovation.